PAVmed (NASDAQ: PAVM - Get Free Report) and InMode (NASDAQ: INMD - Get Free Report) are both small-c

Gainers Nexalin Technology (NASDAQ:NXL) shares increased by 77.8% to $7.61 during Thursday's re

Medicare Advisory Panel recommends maintaining EsoGuard's original gapfill payment basis under the C

Wall Street analysts changed outlook on top names: Evercore raised Salesforce target, Needham raised

Ascendiant Capital analyst Edward Woo maintains PAVmed (NASDAQ:PAVM) with a Buy and raises the pr

PAVmed Inc. (PAVM) Q2 2026 Earnings Call Transcript

On Friday, PAVmed (NASDAQ:PAVM) discussed second-quarter financial results during its earnings call.

PAVmed (NASDAQ:PAVM) reported quarterly losses of $(0.27) per share which beat the analyst consensus

Veris Health accelerated its commercial engagement with OSU-The James Veris Health implantable physi

Recognized 2Q26 revenue of $1.5 million Processed 2,770 EsoGuard ® tests Secured first laboratory be

PAVmed (NASDAQ: PAVM - Get Free Report) and Alpha Tau Medical (NASDAQ: DRTS - Get Free Report) are b

Concert's policy recognizes EsoGuard ® as the only esophageal precancer test meeting its coverage cr

NEW YORK, Aug. 4, 2026 /PRNewswire/ -- Lucid Diagnostics Inc.  (Nasdaq: LUCD) ("Lucid" or the "Compa

Conference Call and Webcast at 8:30 AM ET NEW YORK, July 31, 2026 /PRNewswire/ -- PAVmed Inc.  (Nasd

Conference Call and Webcast at 8:30 AM ET NEW YORK, July 30, 2026 /PRNewswire/ -- Lucid Diagnostics

PAVmed Inc. (PAVM) Shareholder/Analyst Call Prepared Remarks Transcript

Ascendiant Capital analyst Edward Woo maintains PAVmed (NASDAQ:PAVM) with a Buy and lowers the pr

PAVmed Inc. (PAVM) Q1 2026 Earnings Call Transcript

PAVmed Inc. (PAVM) came out with a quarterly loss of $1.17 per share versus the Zacks Consensus Esti

PAVmed (NASDAQ:PAVM) reported quarterly losses of $(1.17) per share which missed the analyst consens

Veris Health progressed commercial expansion and advanced implantable physiological monitor developm

Processed 3,177 EsoGuard ® tests and recognized 1Q26 revenue of $1.3 million, ending quarter with $4

PAVmed (PAVM) doesn't possess the right combination of the two key ingredients for a likely earnings

Conference Call and Webcast at 8:30 AM ET NEW YORK, May 1, 2026 /PRNewswire/ -- PAVmed Inc.  (Nasdaq

Conference Call and Webcast at 8:30 AM ET NEW YORK, April 30, 2026 /PRNewswire/ --  Lucid Diagnostic

NEW YORK, April 24, 2026 /PRNewswire/ -- Lucid Diagnostics Inc.  (Nasdaq: LUCD) ("Lucid" or the "Com

 Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company"), a commercial-stage

NEW YORK, April 23, 2026 /PRNewswire/ -- Lucid Diagnostics Inc.  (Nasdaq: LUCD) ("Lucid" or the "Com

PAVmed shares pull back Thursday, possibly retracing recent gains on news its subsidiary, Lucid Diag

PAVmed Inc. (PAVM) surges as its subsidiary Lucid Diagnostics (LUCD) secures a contract with VA for

Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company"), a commercial-stage,

 PAVmed Inc. (NASDAQ:PAVM) ("PAVmed" or the "Company"), a diversified commercial-sta